Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 2, Issue 2, 2008, Pages 93-98

  Hermans, Michel P ^a   Ahn, Sylvie A ^a   Rousseau, Michel F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Diabetes; Hypertension; Neurohormones; Prevention; Stroke; UKPDS Risk Engine

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROHORMONE; TRIACYLGLYCEROL; UROTENSIN II;

ADULT; AGE; AGED; ALBUMINURIA; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; WAIST CIRCUMFERENCE;

EID: 43049093770     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.02.001     Document Type: Article

References (20)

1. Manson J.E., Colditz G.A., Stampfer M.J., Willett W.C., Krolewski A.S., Rosner B., et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151 (1991) 1141-1147
2. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 (1993) 434-444
3. Stegmayr B., Asplund K., Kuulasmaa K., Rajakangas A.M., Thorvaldsen P., and Tuomilehto J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA project. An ecological study of 18 populations. Stroke 28 (1997) 1367-1374
4. Muntner P., Garrett E., Klag M.J., and Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke 33 (2002) 1209-1213
5. Kothari V., Stevens R.J., Adler A.I., Stratton I.M., Manley S.E., Neil H.A., et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33 (2002) 1776-1781
6. Hermans M.P., Gala J.L., and Buysschaert M. The MTHFR C677T polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with type 2 diabetes. Diabetic Med 23 (2006) 529-536
7. Wang T.J., Larson M.G., Keyes M.J., Levy D., Benjamin E.J., and Vasan R.S. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115 (2007) 1345-1353
8. Lteif A., and Mather K. Insulin resistance, metabolic syndrome and vascular diseases: update and mechanistic linkages. Can J Cardiol 20 Suppl B (2004) 66B-76B
9. Kim J.-A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
10. Sarafidis P.A., and Bakris G.L. Insulin and endothelin: an interplay contributing to hypertension development?. J Clin Endocrinol Metabol 92 (2007) 379-385
11. Hermans M.P., Ahn S.A., Gruson D., and Rousseau M.F. The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. Diabetes Metab Syndr Clin Res Rev 1 (2007) 229-237
12. Stevens R.J., Coleman R.L., Adler A.I., Stratton I.M., Matthews D.R., and Holman R.R. UKPDS 66: risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabetes Care 27 (2004) 201-207
13. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
14. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20;1997: 1183-97.
15. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
16. Hermans M.P., Levy, Morris R.J., and Turner R.C. Comparison of insulin sensitivity tests across a range of glucose tolerance form normal to diabetes. Diabetologia 42 (1999) 678-687
17. Rousseau M.F., Gurné O., Duprez D., Van Mieghem W., Robert A.R., Ahn S.A., et al. For the Belgian Rales Investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. Results from the Rales Neurohormonal Substudy. J Am Coll Cardiol 40 (2002) 1596-1601
18. Van Beneden R., Gurné O., Selvais P.L., Ahn S.A., Robert A.R., Ketelslegers J.M., et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Cardiac Fail 10 (2004) 490-495
19. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 (2006) 1527-1531
20. Lteif A., Vaishnava P., Baron A.D., and Mather K.J. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 56 (2007) 728-734